MX2011008917A - Peptidos vangl1 y vacunas que incluyen los mismos. - Google Patents

Peptidos vangl1 y vacunas que incluyen los mismos.

Info

Publication number
MX2011008917A
MX2011008917A MX2011008917A MX2011008917A MX2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A MX 2011008917 A MX2011008917 A MX 2011008917A
Authority
MX
Mexico
Prior art keywords
peptides
vangl1
same
vaccines including
present
Prior art date
Application number
MX2011008917A
Other languages
English (en)
Inventor
Ryuji Ohsawa
Takuya Tsunoda
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2011008917A publication Critical patent/MX2011008917A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona péptidos aislados o los fragmentos derivados de la SEQ ID NO: 35, que enlazan a un antígeno HLA e inducen linfocitos T citotóxicos (CTL). Los péptídos pueden incluir una de las secuencias de aminoácido mencionadas arriba con sustitución, eliminación, o adición de uno, dos, o varias secuencias de aminoácido. La presente invención también proporciona composiciones farmacéuticas que incluyen estos péptidos. Los péptidos de esta invención pueden usarse para tratar cáncer.
MX2011008917A 2009-03-04 2010-03-01 Peptidos vangl1 y vacunas que incluyen los mismos. MX2011008917A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20924209P 2009-03-04 2009-03-04
PCT/JP2010/001366 WO2010100878A1 (en) 2009-03-04 2010-03-01 Vangl1 peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
MX2011008917A true MX2011008917A (es) 2011-09-09

Family

ID=42709447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008917A MX2011008917A (es) 2009-03-04 2010-03-01 Peptidos vangl1 y vacunas que incluyen los mismos.

Country Status (14)

Country Link
US (1) US20120107333A1 (es)
EP (1) EP2403943A1 (es)
JP (1) JP2012519470A (es)
KR (1) KR20110134446A (es)
CN (1) CN102439147A (es)
AU (1) AU2010219951A1 (es)
BR (1) BRPI1012312A2 (es)
CA (1) CA2753681A1 (es)
IL (1) IL214453A0 (es)
MX (1) MX2011008917A (es)
RU (1) RU2011140168A (es)
SG (1) SG174206A1 (es)
TW (1) TW201043244A (es)
WO (1) WO2010100878A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201211250A (en) * 2010-09-07 2012-03-16 Oncotherapy Science Inc VANGL1 peptides and vaccines including the same
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
KR102492241B1 (ko) * 2022-02-25 2023-01-30 전남대학교산학협력단 Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399569A1 (en) * 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
EP1462456A4 (en) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd TUMOR ANTIGENS
DK2261249T3 (en) * 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
EP1853703B1 (en) * 2005-02-25 2011-04-13 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk polypeptides
BRPI0613970B8 (pt) * 2005-07-27 2021-05-25 Oncotherapy Science Inc composição para o tratamento ou para a prevenção de câncer de cólon compreende uma quantidade farmaceuticamente eficaz de um sirna contra um polinucleotídeo de tom 34
BRPI0717651A2 (pt) * 2006-10-17 2013-12-24 Oncotherapy Science Inc Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1

Also Published As

Publication number Publication date
US20120107333A1 (en) 2012-05-03
EP2403943A1 (en) 2012-01-11
SG174206A1 (en) 2011-10-28
JP2012519470A (ja) 2012-08-30
CN102439147A (zh) 2012-05-02
BRPI1012312A2 (pt) 2017-03-21
IL214453A0 (en) 2011-09-27
AU2010219951A1 (en) 2011-08-25
KR20110134446A (ko) 2011-12-14
WO2010100878A1 (en) 2010-09-10
CA2753681A1 (en) 2010-09-10
TW201043244A (en) 2010-12-16
RU2011140168A (ru) 2013-04-10

Similar Documents

Publication Publication Date Title
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2009025196A1 (ja) Foxm1ペプチドおよびこれを含む薬剤
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
PH12014500720A1 (en) Topk peptides and vaccines including the same
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
MX2009007261A (es) Vacuna de peptido foxp3.
EP3556857A3 (en) Cdc45l peptides and vaccines including the same
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
MX2012008657A (es) Peptidos melk modificados y vacunas que contienen los mismos.
PH12013501105A1 (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
EP2513136A4 (en) PEPTIDES TMEM22 AND VACCINES COMPRISING THEM
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
MX2012011385A (es) Peptidos ect2 y vacunas que los incluyen.
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
TH143303A (th) Tomm34 เปปไทด์ และ วัคซีนที่บรรจุสิ่งเดียวกันนี้
PH12012501935A1 (en) Ect2 peptides and vaccines including the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal